Liquidia (NASDAQ:LQDA) Insider Jason Adair Sells 7,301 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) insider Jason Adair sold 7,301 shares of the firm’s stock in a transaction on Monday, October 12th. The shares were sold at an average price of $28.48, for a total value of $207,932.48. Following the completion of the transaction, the insider owned 177,957 shares of the company’s stock, valued at approximately $5,068,215.36. This represents a 3.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jason Adair also recently made the following trade(s):

• On Friday, August 21st, Jason Adair sold 73,631 shares of Liquidia stock. The stock was sold at an average price of $69.09, for a total transaction of $5,087,165.79.
• On Monday, July 27th, Jason Adair sold 688 shares of Liquidia stock. The shares were sold at an average price of $87.53, for a total transaction of $60,220.64.

Liquidia Price Performance

NASDAQ LQDA traded down $0.86 during trading hours on Tuesday, reaching $26.81. The company’s stock had a trading volume of 3,092,611 shares, compared to its average volume of 5,078,983. The stock has a market cap of $2.40 billion, a PE ratio of 19.57 and a beta of 0.61. Liquidia Corporation has a fifty-two week low of $21.94 and a fifty-two week high of $93.61. The company’s 50-day moving average is $63.40 and its two-hundred day moving average is $61.76. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). The business had revenue of $171.68 million for the quarter, compared to analyst estimates of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The business’s revenue was up 1842.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.49) EPS. Analysts forecast that Liquidia Corporation will post 2.05 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of LQDA. Bank of New York Mellon Corp acquired a new stake in shares of Liquidia during the second quarter worth $29,694,000. Bank of America Corp DE increased its stake in Liquidia by 18.7% in the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after purchasing an additional 360,372 shares during the last quarter. Capricorn Fund Managers Ltd acquired a new position in Liquidia in the first quarter valued at $9,337,000. Eversept Partners LP lifted its position in Liquidia by 33.0% during the first quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock worth $25,565,000 after buying an additional 167,949 shares during the period. Finally, Seven Fleet Capital Management LP lifted its position in Liquidia by 124.5% during the first quarter. Seven Fleet Capital Management LP now owns 204,876 shares of the company’s stock worth $7,732,000 after buying an additional 113,609 shares during the period. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

LQDA has been the subject of a number of recent research reports. Jefferies Financial Group raised shares of Liquidia to a “strong-buy” rating in a research note on Thursday, October 1st. Citigroup reissued a “neutral” rating on shares of Liquidia in a research report on Thursday, October 1st. Wall Street Zen downgraded Liquidia from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Royal Bank Of Canada set a $130.00 price objective on Liquidia in a research report on Friday, July 24th. Finally, HC Wainwright decreased their price objective on Liquidia from $130.00 to $58.00 and set a “buy” rating on the stock in a research note on Friday, October 2nd. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Liquidia presently has a consensus rating of “Hold” and an average target price of $83.69.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reached a global settlement with United Therapeutics that resolves all six pending lawsuits and allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension (PAH). Eliminating years of patent, antitrust and trade-secret litigation reduces regulatory and commercial uncertainty. Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were $222.7 million, while cash and cash equivalents stood at $396.1 million at September 30. Management said it expects to fund the settlement and planned clinical programs from cash and ongoing sales without additional financing. The company also plans to continue developing YUTREPIA and L606.
• Neutral Sentiment: Multiple executives and insiders—including the CEO, CFO, CAO and general counsel—sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales reduced individual holdings but were not discretionary open-market transactions, making them a limited standalone signal of management confidence. Liquidia insider sale filing
• Negative Sentiment: Liquidia will pay United Therapeutics a net $380.7 million: $175 million within 30 business days, $145.4 million in installments during 2027 and $60.3 million related to the antitrust litigation. The outflows could materially reduce its cash cushion and constrain investment, even though management expects to rebuild cash through YUTREPIA sales.
• Negative Sentiment: The company agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label, limiting the product’s addressable market. Liquidia also ended promotion of Treprostinil Injection, eliminating associated commercial revenue opportunities.
• Negative Sentiment: Recent insider activity remains heavily tilted toward selling—106 sales versus one purchase over six months—and a report highlighted a chairman’s share sale. Separately, a law firm announced an investor investigation related to disclosure of YUTREPIA litigation risks, adding potential reputational and legal uncertainty. Liquidia Negatively Rated Stock Pick of the Week

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).